二肽基肽酶4抑制用于急性移植物抗宿主病预防
这项两阶段2期非随机试验评估西格列汀联合他克莫司和西罗莫司预防急性GVHD的效果。36例可评估患者接受清髓性异基因移植后,第100天II-IV级急性GVHD发生率为5%(95%CI 1-16),III-IV级为3%(95%CI 0-12),1年非复发死亡率为零。
要点
- 西格列汀联合他克莫司和西罗莫司可使第100天II-IV级急性GVHD发生率降至5%。
- 1年非复发死亡率为零,复发累积发生率26%,慢性GVHD累积发生率37%。
- 该方案毒性反应与常规异基因移植患者相似,但需随机对照试验验证。
核心结论
- 在非随机试验中,西格列汀联合他克莫司和西罗莫司使清髓性异基因造血干细胞移植后第100天II-IV级急性GVHD发生率较低。
研究设计与样本
- 两阶段2期临床试验,评估西格列汀联合他克莫司和西罗莫司能否将第100天II-IV级急性GVHD发生率从30%降至不超过15%。
- 36例可评估患者接受清髓性预处理后行动员外周血干细胞移植,中位年龄46岁(范围20-59),供者为相合亲缘或非亲缘。
- 西格列汀口服600 mg每12小时一次,从移植前1天至移植后14天。
主要发现
- 第100天急性GVHD发生于2/36例患者,II-IV级GVHD发生率为5%(95%CI 1-16),III-IV级为3%(95%CI 0-12)。
- 1年非复发死亡率为零。
- 1年复发累积发生率为26%(95%CI 13-41),慢性GVHD累积发生率为37%(95%CI 22-53)。
- 1年无GVHD无复发生存率为46%(95%CI 29-62)。
- 毒性反应与接受异基因干细胞移植患者相似。
临床怎么用
- 对于接受清髓性异基因造血干细胞移植的患者,可考虑西格列汀联合他克莫司和西罗莫司作为急性GVHD预防方案。
- 需注意该方案来自非随机2期试验,应用时应结合患者具体情况并等待进一步验证。
局限性
- 非随机试验,无对照组,样本量较小(36例可评估患者)。
- 单中心或有限中心研究,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dipeptidyl peptidase 4 (DPP-4; also known as CD26), a transmembrane receptor expressed on T cells, has a costimulatory function in activating T cells. In a mouse model, down-regulation of CD26 prevented graft-versus-host disease (GVHD) but preserved graft-versus-tumor effects. Whether inhibition of DPP-4 with sitagliptin may prevent acute GVHD after allogeneic stem-cell transplantation is not known. METHODS: We conducted a two-stage, phase 2 clinical trial to test whether sitagliptin plus tacrolimus and sirolimus would reduce the incidence of grade II to IV acute GVHD from 30% to no more than 15% by day 100. Patients received myeloablative conditioning followed by mobilized peripheral-blood stem-cell transplants. Sitagliptin was given orally at a dose of 600 mg every 12 hours starting the day before transplantation until day 14 after transplantation. RESULTS: A total of 36 patients who could be evaluated, with a median age of 46 years (range, 20 to 59), received transplants from matched related or unrelated donors. Acute GVHD occurred in 2 of 36 patients by day 100; the incidence of grade II to IV GVHD was 5% (95% confidence interval [CI], 1 to 16), and the incidence of grade III or IV GVHD was 3% (95% CI, 0 to 12). Nonrelapse mortality was zero at 1 year. The 1-year cumulative incidences of relapse and chronic GVHD were 26% (95% CI, 13 to 41) and 37% (95% CI, 22 to 53), respectively. GVHD-free, relapse-free survival was 46% (95% CI, 29 to 62) at 1 year. Toxic effects were similar to those seen in patients undergoing allogeneic stem-cell transplantation. CONCLUSIONS: In this nonrandomized trial, sitagliptin in combination with tacrolimus and sirolimus resulted in a low incidence of grade II to IV acute GVHD by day 100 after myeloablative allogeneic hematopoietic stem-cell transplantation. (Funded by the National Heart, Lung, and Blood Institute; ClinicalTrials.gov number, NCT02683525.).
引用
- Farag SS, Abu Zaid M, Schwartz JE, et al. Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease. N Engl J Med. 2021. PMID: 33406328. doi:10.1056/NEJMoa2027372
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。